MEMartin Eberhardt

Martin Eberhardt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin Eberhardt has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy

    by Christopher Lischer, Martin Eberhardt, Cindy Flamann, Johannes Berges, Esther Güse, Anja Wessely, Adrian Weich, Jimmy Retzlaff, Jan Dörrie, Niels Schaft, et al.

    Background Tumor-associated antigens and their derived peptides constitute an opportunity to design off-the-shelf mainline or adjuvant anti-cancer immunotherapies for a broad array of patients. A performant and rational antigen selection pipeline would lay the foundation for immunotherapy trials with the potential to enhance treatment, tremendously benefiting patients suffering from rare, understudied cancers. Methods We present an experimentally validated, data-driven computational pipeline that selects and ranks antigens in a multipronged approach. In addition to minimizing the risk of immune-related adverse events by selecting antigens based on their expression profile in tumor biopsies and healthy tissues, we incorporated a network analysis-derived antigen indispensability index based on computational modeling results, and candidate immunogenicity predictions from a machine learning ensemble model relying on peptide physicochemical characteristics. Results In a model study of uveal melanoma, Human Leukocyte Antigen (HLA) docking simulations and experimental quantification of the peptide–major histocompatibility complex binding affinities confirmed that our approach discriminates between high-binding and low-binding affinity peptides with a performance similar to that of established methodologies. Blinded validation experiments with autologous T-cells yielded peptide stimulation-induced interferon-γ secretion and cytotoxic activity despite high interdonor variability. Dissecting the score contribution of the tested antigens revealed that peptides with the potential to induce cytotoxicity but unsuitable due to potential tissue damage or instability of expression were properly discarded by the computational pipeline. Conclusions In this study, we demonstrate the feasibility of the de novo computational selection of antigens with the capacity to induce an anti-tumor immune response and a predicted low risk of tissue damage. On translation to the clinic, our pipeline supports fast turn-around validation, for example, for adoptive T-cell transfer preparations, in both generalized and personalized antigen-directed immunotherapy settings.


  • Open Access

    Supplemental Figures and Tables from The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages

    by Dimitrios Mougiakakos, Christian Bach, Martin Böttcher, Fabian Beier, Linda Röhner, Andrej Stoll, Michael Rehli, Claudia Gebhard, Christopher Lischer, Martin Eberhardt, et al.

    Supplemental Figures 1-24 and Tables 1-3

  • Open Access

    Supplemental Figures and Tables from The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages

    by Dimitrios Mougiakakos, Christian Bach, Martin Böttcher, Fabian Beier, Linda Röhner, Andrej Stoll, Michael Rehli, Claudia Gebhard, Christopher Lischer, Martin Eberhardt, et al.

    Supplemental Figures 1-24 and Tables 1-3

  • Open Access

    Spectral Observations at the CILBO Observatory: Calibration andData Sets

    by Joe Zender, Detlef Koschny, Regina Rudawska, Salvatore Vicinanza, Stefan Loehle, Martin Eberhardt, Arne Meindl, Hans Smit, Lionel Marraffa, Rico Landman, et al.

    This talk will introduce the The Canary Island Long-Baseline Observatory (CILBO), a double station meteor camera setup located on the Canary Islands and operated by ESA’s Meteor Research Group since 2010. Our observations of meteors are obtained in the visual wavelength band by intensified video cameras from both stations, supplemented by an intensified video camera mounted with a spectral grating at one of the locations. The cameras observe during cloudless and precipitation-free nights and data are transferred to a main computer located at ESA/ESTEC once a day. The image frames that contain spectral information are calibrated, corrected, and finally processed into line intensity profiles. An ablation simulation, based on Bayesian statistics using a Markov-Chain Monte-Carlo method, allows to determine a parameter space, including the ablation temperatures, chemical elements and their corresponding line intensities, to fit against the line intensity profiles of the observed meteor spectra. The algorithm is presented in this talk. Several hundred spectra have been processed and will be made available through the Guest Archive Facility of the Planetary Science Archive of ESA.   

  • Einführung, Struktur und Zusammenfassung

    by Andreas Pfnür, Martin Eberhardt, Thomas Herr

  • Open Access

    Network- and systems-based re-engineering of dendritic cells with non-coding RNAs for cancer immunotherapy

    by Xin Lai, Florian S. Dreyer, Martina Cantone, Martin Eberhardt, Kerstin F. Gerer, Tanushree Jaitly, Steffen Uebe, Christopher Lischer, Arif Ekici, Jürgen Wittmann, et al.

    Dendritic cells (DCs) are professional antigen-presenting cells that induce and regulate adaptive immunity by presenting antigens to T cells. Due to their coordinative role in adaptive immune responses, DCs have been used as cell-based therapeutic vaccination against cancer. The capacity of DCs to induce a therapeutic immune response can be enhanced by re-wiring of cellular signalling pathways with microRNAs (miRNAs).


  • Transcriptional analysis identifies potential biomarkers and molecular regulators in pneumonia and COPD exacerbation

    by W Bertrams, K Griss, M Han, M Eberhardt, K Seidel, A Klemmer, A Sittka-Stark, S Hippenstiel, N Suttorp, F Finkernagel, et al.

    Acute infections of the lower respiratory tract like community-acquired pneumonia (CAP) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD) constitute the third most frequent cause of death worldwide. Urgent medical needs are early diagnosis and differential diagnosis as well as profound pathophysiological insights. Chronic obstructive pulmonary disease (COPD) is a poorly reversible condition characterized by airflow limitation and decrease of lung function. Community acquired pneumonia (CAP) is clinically defined by a sudden onset of severe illness that is accompanied by signs of lower respiratory tract infection, fever, cough and dyspnoea. We investigated the PBMC RNA profile of 5 healthy donors, 6 pneumonia patients and 6 COPD patients with acute exacerbations. From a total of 1,621 differentially expressed genes between CAP and AECOPD, we used Weighted Gene Co-expression Network Analysis (WGCNA) to extract a cluster of 120 genes (the module I) that exhibited the highest potency of disease type discrimination. We combined differentially regulated microRNAs and mRNAs into a regulatory network that functionally integrates the major distinctive factors between CAP and AECOPD. We identified the main hub molecule of this network, the transcription factor hepatocyte nuclear factor 4 alpha (HNF4A). Furthermore, other members of this network, such as MCC and MUC1, were found to be good discriminators between AECOPD and CAP. Likewise, we gathered several microRNAs, e.g. miR-545-3p and miR-519c-3p, which proved to be capable of separating AECOPD and CAP. The described RNA molecules may serve as accessible markers of disease in peripheral blood.